Medistim Opens a Direct Sales Office in Japan
Medistim ASA announced on February 3rd the opening of a direct sales operation in Japan, effective March 16, 2026. The expansion into a direct sales model in Japan is intended to strengthen the company’s market presence and enhance customer engagement in one of its key strategic markets. This initiative underscores Medistim’s continued commitment to delivering high-quality service and clinical support to cardiovascular surgeons globally and aligns with the Company’s long-term global growth strategy.
Medistim maintains a very strong market position in Japan, where approximately 90% of the estimated 17,000 annual coronary artery bypass graft (CABG) procedures are supported by the company’s Transit Time Flow Measurement (TTFM)technology.
Future growth in the Japanese market is expected to be driven by continued conversion from installed base systems utilizing TTFM-only functionality to next-generation platforms integrating both TTFM and High-Frequency Ultrasound(HFUS). This represents a meaningful value-enhancement opportunity within the existing customer base.
In addition, the vascular surgery segment presents significant incremental growth potential, supported by untapped procedural volumes and broader clinical adoption of Medistim’s technology portfolio.
“We are pleased to announce this strategic initiative, which will further strengthen our engagement with customers in Japan,” said Kari E. Krogstad, President and CEO of Medistim ASA. “The establishment of a direct presence in Japan has been under evaluation for some time, and we have now resolved to proceed. We are well prepared for this transition, with key personnel for the new subsidiary already in place.
Our experience from other markets demonstrates that a direct operating model enhances customer proximity, supports sustainable revenue growth, and contributes positively to margins, while ensuring the highest standards of service and clinical support. We are confident that this step will reinforce our market position and unlock additional growth opportunities in Japan.
At the same time, we would like to acknowledge our long-standing distribution partner, Nippon BXI K.K., for more than three decades of collaboration and for their significant contribution to expanding Medistim’s presence in the Japanese market. We will work closely together to secure a seamless transition ahead of the conclusion of the distribution agreement on March 16, 2026.”
The newly established operating subsidiary, Medistim Japan K.K., is a Japanese corporation wholly owned by Medistim ASA. The company is headquartered in Minato, Tokyo, and will serve as the platform for Medistim’s direct commercial operations in the Japanese market.
